Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Munich - Delayed Quote EUR

InnoCan Pharma Corp (IP4.MU)

Compare

0.1395

-0.0120

(-7.92%)

As of 8:04:22 AM GMT+1. Market Open.

TSX Penny Stocks Under CA$60M Market Cap: Discovering Promising Opportunities

As the Canadian TSX index experiences a modest 3% rise amidst stabilizing yields and contained inflation, investors are increasingly looking for opportunities in smaller, potentially high-growth segments of the market. Penny stocks, while an older term, continue to capture attention due to their ability to represent smaller or newer companies with significant upside potential. By focusing on those with strong financials and clear growth paths, investors can uncover promising opportunities...

Simply Wall St. 4 hours ago

FRACF

MJGCF

INNPF
Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful outcome from the compassionate treatment of a female donkey with its innovative liposomal CBD injection (LPT-CBD). Innocan's innovative therapy provided quick and sustained pain relief, significantly improving mobility in an elderly female donkey suffering from osteoarthritis.

CNW Group 15 days ago

INNPF

INN

INN-PE
Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its subsidiary, BI Sky Global (BI), successfully completed the Human Repeated Insult Patch Test (HRIPT) for Sensitization and Irritation Testing, ensuring the safety of its cosmetic products. HRIPT is the personal care industry's standard safety test for cosmetic, OTC drug, and topical medical devices.

CNW Group 27 days ago

INN

INN-PE

INN-PF
TSX Penny Stock Picks For January 2025

As we step into 2025, the Canadian market is navigating a landscape shaped by new U.S. policies on energy, immigration, tariffs, and technology. With the TSX index showing resilience since Inauguration Day and potential rate adjustments by the Bank of Canada on the horizon, investors are keenly observing these developments. Amidst this backdrop, penny stocks—often representing smaller or emerging companies—remain a niche yet intriguing investment area for those seeking growth opportunities...

Simply Wall St. 28 days ago

INNPF

MGPHF

CPCPF
FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the second consecutive year.

CNW Group last month

INN

INN-PE

INN-PF
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60

Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 3,177,223 Units at a price of C$0.20 per Unit (the "Offering Price") for aggregate gross proceeds of $635,444.60.

CNW Group last month

INN

INN-PE

INN-PF
InnoCan Pharma Leads Our Trio Of TSX Penny Stock Picks

The Canadian market has experienced some pullback recently, driven by political uncertainty and profit-taking after a strong year of growth. Despite this volatility, the underlying economic fundamentals remain robust, providing a landscape where smaller companies can thrive. Penny stocks, though often overlooked due to their historical connotations, continue to offer intriguing opportunities for investors seeking value and growth potential in financially sound enterprises.

Simply Wall St. last month

NBMFF

NNOMF

INNPF
Innocan Pharma Announces Private Placement of Units

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete a non-brokered private placement of up to [3,500,000] units of the Company (the "Units") at a price of [C$0.20] per Unit for gross proceeds up to C$700,000 plus 15% over allotment options (the "Offering"). The Offering is expected to close on or around December 31, 2024.

CNW Group 2 months ago

INNPF

INN

INN-PE
Innocan Pharma Provides its Annual "State of Research and Development" Update for 2024

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share its annual "State of Research and Development" update for 2024. This year, the Company achieved significant milestones in advancing research and development for its drug delivery platforms as well as its intellectual

CNW Group 2 months ago

INNPF

INN

INN-PE
3 TSX Penny Stocks With Market Caps Over CA$20M To Watch

The Canadian market is experiencing strong momentum as it heads into 2025, supported by a resilient consumer base, rising corporate profits, and the beginning of a rate-cutting cycle. Amidst this positive backdrop, investors may find opportunities in areas that have traditionally been overlooked, such as penny stocks. While the term "penny stock" might seem outdated, these smaller or newer companies can still offer significant growth potential when backed by solid financials and fundamentals.

Simply Wall St. 2 months ago

ZMDTF

TNREF

INNPF
Innocan Pharma Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to report positive results from a basic safety assessment study, evaluating LPT-CBD administered as a single injection in Göttingen minipigs.

CNW Group 2 months ago

INNPF

INN

INN-PE
Innocan Pharma Reports Third Quarter 2024 Financial Results

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its consolidated financial results for the three and nine-month periods ended September 30, 2024.

CNW Group 3 months ago

INN

INN-PE

INN-PF
Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, announced that it has taken the strategic decision to focus its development resources on advancing its groundbreaking Liposome Platform Technology-Cannabidiol (LPT-CBD), a monthly injectable treatment for chronic pain in both animals and humans. This decision follows encouraging progress with the U.S. Food and Drug Administration (FDA).

CNW Group 3 months ago

INNPF

INN

INN-PE
InnoCan Pharma Leads 3 Promising Penny Stocks On TSX

The Canadian market is navigating a landscape of shifting expectations around interest rates, with the recent economic data prompting a reassessment of future rate paths. In this context, identifying promising investments requires focusing on companies with strong fundamentals and growth potential. Although "penny stocks" may seem like an outdated term, they still represent smaller or newer companies that can offer significant value when backed by solid financials. Here, we explore three such...

Simply Wall St. 3 months ago

HMENF

SLRRF

INNPF
Innocan Pharma to Present at the 2024 ThinkEquity Conference

HERZLIYA, Israel and CALGARY, Alberta, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in chronic pain management via Liposomal CBD drug products, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highli

GlobeNewswire 4 months ago

INNPF

INN

INN-PE
Innocan Pharma to Participate at the ThinkEquity 2024 Investor Conference in New York Also Announces Relaunch of Updated Website for Enhanced Investor Experience

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in chronic pain management via Liposomal CBD drug products, is pleased to announce that it will be presenting at the 2024 ThinkEquity Investor Conference taking place on October 30 at the Mandarin Oriental Hotel in New York, NY.

CNW Group 4 months ago

INNPF

INN

INN-PE
Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce promising results from a multi-year compassionate therapy using repeated liposomal-CBD (LPT-CBD) injections for pain relief in dogs with naturally-occurring osteoarthritis. The therapy consistently demonstrated pain reduction and improved mobility, with effects lasting for several weeks after each injection as expected

CNW Group 4 months ago

INN

INN-PE

INN-PF
Innocan Pharma Celebrates Dr. Joseph Pergolizzi's Recognition Among Stanford University's List of the Top 2% Most-Cited Scientists Worldwide

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that Dr. Joseph V. Pergolizzi, Jr., M.D., a member of Innocan's Scientific Advisory Board, has been recognized among the top 2% most-cited scientists in the world in a new list published by Stanford University. This achievement underscores Dr. Pergolizzi's long-term contribution to medical science and his influential r

CNW Group 4 months ago

INNPF

INN

INN-PE
Innocan Pharma Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has received a positive response from the U.S. Food and Drug Administration (FDA) following Innocan's successful pre-Investigational New Drug (pre-IND) Type B meeting with the FDA held in July, for its lead drug product Liposomal Technology-CBD (LPT-CBD).

CNW Group 5 months ago

INNPF

INN

INN-PE
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has completed its previously announced non-brokered private placement offering of 5,025,725 units of the Company (the "Units") at a price of C$0.22 per Unit for gross proceeds of C$1,105,659.50 (the "Offering").

CNW Group 5 months ago

INN

INN-PE

INN-PF

Performance Overview

Return	IP4.MU	S&P/TSX Composite index
YTD	+11.16%	+3.11%
1-Year	-35.57%	+18.55%
3-Year	-67.14%	+20.28%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

InnoCan Pharma Corp (IP4.MU)

TSX Penny Stocks Under CA$60M Market Cap: Discovering Promising Opportunities

Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis

Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone

TSX Penny Stock Picks For January 2025

FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025

Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60

InnoCan Pharma Leads Our Trio Of TSX Penny Stock Picks

Innocan Pharma Announces Private Placement of Units

Innocan Pharma Provides its Annual "State of Research and Development" Update for 2024

3 TSX Penny Stocks With Market Caps Over CA$20M To Watch

Innocan Pharma Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs

Innocan Pharma Reports Third Quarter 2024 Financial Results

Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand

InnoCan Pharma Leads 3 Promising Penny Stocks On TSX

Innocan Pharma to Present at the 2024 ThinkEquity Conference

Innocan Pharma to Participate at the ThinkEquity 2024 Investor Conference in New York Also Announces Relaunch of Updated Website for Enhanced Investor Experience

Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs

Innocan Pharma Celebrates Dr. Joseph Pergolizzi's Recognition Among Stanford University's List of the Top 2% Most-Cited Scientists Worldwide

Innocan Pharma Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting

Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options

Performance Overview